• 1
    Hirsh J, Dalen J, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119: 8S21S.
  • 2
    Harder S, Thurmann P. Clinically important drug interactions with anticoagulants. An update. Clin Pharmacokinet 1996; 30: 41644.
  • 3
    Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 113951.
  • 4
    Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36: 38699.
  • 5
    Stangier J, Staehle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008; 47: 4759.
  • 6
    Stangier J, Rathgen K, Staehle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64: 292303.
  • 7
    Stangier J, Rathgen K, Staehle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010; 49: 25968.
  • 8
    Stangier J, Staehle H, Rathgen K, Roth W, Reseski K, Koernicke T. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin. J Clin Pharmacol; DOI: 10.1177/0091270010393342.
  • 9
    Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. 2001.
  • 10
    Gastonguay M. Full model estimation approach for covariate effects: inference based on clinical importance and estimation precision. AAPS J 2004; 6(Suppl. 1): 3431.
  • 11
    Ette EI. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 1997; 37: 48695.
  • 12
    Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN) – a perl module for NONMEM related programming. Comput Methods Programs Biomed 2004; 75: 8594.
  • 13
    Mueck W, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Kalebo P, Muelhofer E, Misselwitz F, Eriksson BI. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008; 100: 45361.
  • 14
    Veyrat-Follet C, Vivier N, Trellu M, Dubruc C, Sanderink GJ. The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials. J Thromb Haemost 2009; 7: 55965.
  • 15
    Boxenbaum H. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 1982; 10: 20127.
  • 16
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 3141.